Endocrine Pathology

Official Twitter Page of the Endocrine Pathology Society and its companion journal, Endocrine Pathology #EndoPath #USCAP #EndoPathSociety #EndocrinePathology

[Endocrine Pathology @EndoPath]

Interesting #EndoPath data? Send us your article! Fast turn around & expert reviewers! Make our journal your voice! https://t.co/4QtKLi5zBo

[Endocrine Pathology @EndoPath]

Is it time to move beyond the typical/atypical carcinoid classification? Using data from >700 pulmonary NETs, researchers developed a reproducible grading system (Ki-67 and mitotic count) that outperformed traditional histology in predicting outcome.

https://t.co/EBh6pIuQPC

[Endocrine Pathology @EndoPath]

New molecular insights into GEPNET G3: Multi-omic profiling shows these tumors are biologically distinct from neuroendocrine carcinomas, retain features of well-differentiated NETs and harbor potentially actionable alterations in 25% of cases.

https://t.co/GTleRrvSN1

[Endocrine Pathology @EndoPath]

66,000+ thyroid nodules. 132 studies. One clear message: molecular testing reduces unnecessary surgery for indeterminate thyroid nodules without compromising cancer detection. Second-generation platforms deliver the greatest benefit.

https://t.co/C3bAXmJgpa

[Endocrine Pathology @EndoPath]

Can AI identify PitNET lineage from routine H&E slides alone? An attention-guided neural network achieved high scores and uncovered lineage-specific morphologic patterns, highlighting the potential of AI to support pituitary tumor classification.

https://t.co/9C4K3bqQeA

[Endocrine Pathology @EndoPath]

Can age influence outcome in poorly differentiated thyroid carcinoma? In this study of adults ≤45 years, PDTC showed surprisingly favorable outcomes despite high-grade histology. Distinct molecular features may potentially underlie the improved survival.

https://t.co/CJUQ5CRkhF

[Endocrine Pathology @EndoPath]

New study by @PathDocBoston and team: Among 324 thyroid tumors of uncertain malignant potential (UMP) diagnosed over 20 years, no recurrences or metastases were observed, even after up to 15 years of follow-up. Findings support conservative management!

https://t.co/BTI7qG9Puc

[Endocrine Pathology @EndoPath]

New research from the journal highlights that Ki67-based grading (G1–G3) may better predict outcomes in pulmonary NETs than current carcinoid classification, supporting a shift toward a more precise, clinically relevant system. 🔬📊

https://t.co/oG8t5jhyOe

[Springer Pathology @SpringerPath]

An image in @EndoPath details a 40-year-old woman with a rapidly enlarging thyroid nodule and lymph node metastases. Histological analysis revealed a malignant small round blue cell tumor, leading to a diagnosis of thyroblastoma.

https://t.co/bPtO6eFSSx

[Endocrine Pathology @EndoPath]

Cortex deep-dive!

CYP11B2-guided NGS identifies higher frequency of aldosterone-driver mutations in APM from primary aldosteronism vs donor adrenals, with CACNA1D predominating. APM genotype also associates with coexisting lesions and surgical outcomes.

https://t.co/5e8Enmnc6u

[Endocrine Pathology @EndoPath]

A nationwide study of familial small intestine neuroendocrine tumors reveals distinct features - more frequent multifocal tumors & carcinoid syndrome - yet similar prognosis to sporadic cases.

Key insight: biology differs, outcomes don’t.

https://t.co/8sOr0329Wt

[Springer Pathology @SpringerPath]

Research published in @EndoPath presents genetic insights from adrenal tumors in a MEN1 patient. The study identifies mutations in TP53 and NF1 linked to malignancy, raising awareness of increased cancer risk in MEN1 patients.

https://t.co/4nJedvhu09

[Endocrine Pathology @EndoPath]

Whole-exome sequencing of adrenal tumors from a MEN1 patient reveals shared mutations between adenoma and carcinoma, suggesting a possible biological link - read it here:

https://t.co/Fxox3RRA79

[Endocrine Pathology @EndoPath]

RAS mutations are common in thyroid nodules, but what do they mean clinically?

In 354 nodules, isolated RAS was often linked to benign/low-risk lesions, while RAS + additional mutations (e.g., EIF1AX, TERT) significantly increased tumor aggressiveness.

https://t.co/F7AvCyqMow

[Endocrine Pathology @EndoPath]

Peer review is the foundation of high-quality pathology research.

We thank the reviewers recognized in this issue of Endocrine Pathology for their expertise, rigor, and commitment to advancing the field. Your work strengthens every paper we publish. 🔬

https://t.co/43DvuXi4fI

[Endocrine Pathology @EndoPath]

Pediatric adrenocortical carcinoma is not just “small adult ACC.”

Different biology, different prognosis - and major therapeutic consequences for children.

This review highlights why accurate pathologic assessment matters more than ever!

https://t.co/GeW4zgAxR1

[Endocrine Pathology @EndoPath]

Can histoarchitecture predict genotype in paragangliomas?

In this study of 104 PGLs, AI-based analysis of reticulin architecture accurately predicted germline cluster 1 status, bridging histopathology and molecular classification.

Read more:

https://t.co/GQdqF6jsE9

[Endocrine Pathology @EndoPath]

New article highlight!

EBV-positive neuroendocrine carcinoma of the nasopharynx shows a distinct, high-TMB genomic profile with potentially actionable alterations - supporting recognition as a unique disease entity.

https://t.co/uVP1r28WOa

[Endocrine Pathology @EndoPath]

🔬New in Endocrine Pathology!

Proteomic analysis of bilateral macronodular adrenocortical disease, a rare cause of Cushing syndrome, identifies 3 distinct protein patterns linked to pathology and genetics - opening new diagnostic perspectives.

https://t.co/G2HamWX2U8

[Springer Pathology @SpringerPath]

@EndoPath reports on EBV-positive neuroendocrine carcinoma of the nasopharynx, a rare cancer with distinct molecular features. Whole-exome sequencing reveals high mutational burden and key mutations in TP53, APC, and PROK2.

https://t.co/Uvs4h3JESM

[Endocrine Pathology @EndoPath]

New in Endocrine Pathology!

A fascinating case of a non-invasive follicular cell-derived spindle cell thyroid neoplasm with an NRAS p.Q61R mutation - expanding what we think we know about thyroid tumors! 👩🏻‍⚕️👨🏻‍⚕️

Read more ➡️ https://t.co/iFoXZI3qB6 #PathTwitter